Other languages Appili Therapeutics Inc.

Equities

APLI

CA03783R1073

Market Closed - Toronto S.E. Other stock markets 08:56:30 02/05/2024 pm IST			5-day change	1st Jan Change
0.035 ^CAD	0.00%		-12.50%	0.00%

26/04	Appili Therapeutics Inc. announced that it has received CAD 0.3 million in funding	CI
02/04	Appili Therapeutics To be Acquired by Aditxt, Inc.	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Appili Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13/02
Appili Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	15/11
Appili Therapeutics Inc. Appoints Prakash Gowd to its Board of Directors	14/11
Appili Therapeutics Q2 Net Loss and Comprehensive Loss Narrows Vs a Year Ago	14/11
Appili Therapeutics Inc. Secures Commitment for Second Stage of Funding for ATI-1701 from U.S. Air Force Academy	25/23/25
Appili Therapeutics Inc. Announces Demise of Rochelle Stenzler, as the Director of the Company	25/23/25
Materials stocks drag TSX to one-month low	25/23/25
Appili Therapeutics Announces U.S. FDA Approval of Likmez (ATI-1501) Metronidazole Oral Suspension	25/23/25
Appili gets US FDA approval for oral antibiotic solution	25/23/25
Appili Therapeutics Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	12/23/12
Appili Therapeutics Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23/23/23
Appili Therapeutics Net Loss of $0.08 Per Share For FY 2023	23/23/23
Appili Therapeutics Inc. Secures Contract for ATI-1701 Funding from the U.S. Air Force Academy	08/23/08
Appili Therapeutics Inc. Appoints Gary Nabors as Chief Development Officer	03/23/03
Appili Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/23/14
Appili Therapeutics Narrows 2022 Net Loss Compared with Final 9 Months of 2021	14/23/14
Appili Therapeutics Inc. and Saptalis Pharmaceuticals LLC Announce That FDA Accepts the ATI-1501 NDA	08/23/08
Appili Therapeutics Inc. Announces Executive Appointments	17/23/17
Appili Therapeutics Inc. Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole	13/23/13
Appili Therapeutics Inc. Announces Management Changes	14/22/14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Appili Therapeutics Inc.

Equities

APLI

CA03783R1073

Other languages

Filters